Brind.
  1. Recursion Pharmaceuticals filed documents with the SEC regarding CEO stock sales, while Morgan Stanley cut the price target for the company.

CEO Christopher Gibson sold company shares of Recursion Pharmaceuticals.

1 report, 1 independent Updated Aug 21
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

CEO Christopher Gibson sold company shares of Recursion Pharmaceuticals.

Who's involved

What this event is mainly about
Christopher GibsonRecursion (United States)

Keep exploring

Part of

Recursion Pharmaceuticals filed documents with the SEC regarding CEO stock sales, while Morgan Stanley cut the price target for the company. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Insider MonkeyRecursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares We recently published 10 Stocks Crash as AI Glow Fades. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of We